Introduction {#sec1-1}
============

MicroRNAs (miRNAs), a class of short noncoding RNA molecules, are proposed as promising biomarkers for early cancer detection and accurate prognosis, as well as targets for efficient treatment. Some miRNAs are post-transcriptional regulators of gene expression and implicated in central biological processes such as cell proliferation, differentiation and apoptosis ([@ref1], [@ref2]). Endometriosis is a common disease of reproductive-age women, which has complex pathogenesis. The lesions are extensive, highly invasive and recu-rrent, presenting malignant clinical behavior ([@ref3], [@ref4]). With the development of antisense technology and gene therapy, miRNA is expected to become a new strategy in endometriosis diagnosis and treatment ([@ref5], [@ref6]). It has been proved presently that miRNAs reside widely in eukaryotes, and are the largest gene family, participating and regulating various important life processes including cell differentiation, prolife-ration and apoptosis ([@ref7]). As a method and result of the epigenetic modifications, latest research indicates that miRNA may play important role in the occurrence, development and prognosis of endometriosis, thus providing novel approach for the diagnosis and therapy of endometriosis. MiRNAs are key regulatory elements that control many genes expression and play crucial roles in many biological processes ([@ref8]). Meta-analysis of mass miRNA expression profiling may uncover potential regulatory mechanisms by which microRNAs result in endometriosis.

Materials and Methods {#sec1-2}
=====================

Search strategies and study selection {#sec2-1}
-------------------------------------

PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), Embase (<http://www.elsevier.com/online-tools/-embase>), Web of Science (<http://thomsonreuters.com/thomson-reuters-web-of-science/>), Ovid Med-line (<http://gateway.ovid.com>) were used to search for endometriosis miRNA expression profiling studies published from January 2003 to October 2014 (last accessed on 20 October 2014), by means of the key words: endometriosis AND microRNA.

Eligible studies had to meet the following criteria: (a) they were miRNA expression profiling studies in endometriosis patients; (b) they used tissue samples obtained from surgically resected endometriosis and corresponding eutopic or normal tissues for comparison; (c) use of miRNA microarray methods; (d) publishing a cut-off criteria of differentially expressed miRNAs. Therefore, the miRNA profiling studies using the serum samples of endometriosis patients or endometriosis cells *in vitro* were excluded. Review articles of miRNA expression profiles in endometriosis were also excluded. As repeated efforts can improve reliability and reduce error, valuable candidate miRNAs in this paper are defined as those validated and consistently reported by at least two studies.

Data abstraction {#sec2-2}
----------------

Two investigators (SW and YK) independently evaluated and extracted the data with the standard protocol and with all the discrepancies resolved by a third investigator (HX). From the full text and corresponding supplement information, the following eligibility items were collected and recorded for each study: author, journal and year of publication, location of study, selection and characteristics of recruited endometriosis patients, platform of miRNA expression profiling, author defined cut-off criteria of statistically differentially expressed miRNAs and the list of up- and down-regulated miRNA features, and their corresponding fold change. Each included studies comparing miRNA expression between surgically resected endometriosis tissues and eutopic endometrium or normal tissues provided a list of differentially expressed miRNAs.

MiRNA target prediction and pathway enrichment analysis {#sec2-3}
-------------------------------------------------------

Consensus targets were defined as genes predicted by at least two algorithms of four target prediction tools, including TargetScan, PicTar, miRanda, and miRDB. Although all three of these articles described the expression profile of miRNAs in endometriosis, they did not systematically predict the biological process and pathway of the identified miRNAs. Therefore, we used GeneCodis web tool (<http://genecodis.dacya.ucm.es/>)([@ref9], [@ref10]) to predict the biological process (GO process) and to perform pathway enrichment analysis (KEGG and Panther pathways) of all miRNAs that were identified as consistently expressed miRNAs in the eligible references.

Results {#sec1-3}
=======

Selection and overview of the datasets {#sec2-4}
--------------------------------------

A total of 194 related literatures were indexed in PubMed, Embase, Web of Science and Ovid database. According to the inclusion criteria and identification of duplicate publication, only 12 publications seemed to meet all of the inclusion criteria and none of the exclusion criteria ([Figure 1](#F1){ref-type="fig"}). The characteristics of these studies are listed in [Table 1](#T1){ref-type="table"} in chronological order of the published time ([Table 1](#T1){ref-type="table"}).

![A flow diagram of the literature search and study selection used in this study](IJBMS-18-423-g001){#F1}

###### 

Twelve microarray-based human endometriosis miRNA expression profiling studies

  First author (reference)   Year   Region      Assay type                                  Number of samples\*   Cut-off criteria    Up-regulated miRNAs   Down-regulated miRNAs
  -------------------------- ------ ----------- ------------------------------------------- --------------------- ------------------- --------------------- -----------------------
  Pan Q (2)                  2007   USA         MirVana RNA isolation and enrichment kits   4 pairs+4 N           *P*\<0.05           48                    17
  Toloubeydokhti T (11)      2008   USA         TaqMan MicroRNA Array                       5 pairs+5 N+4 E       5 pairs + 5 N+4 E   1                     2
  Ohlsson Teague EM (12)     2009   Australia   qRT-PCR                                     7 pairs               *P*\<0.05 FC\>1.5   14                    8
  Filigheddu N (8)           2010   Italy       TaqMan MicroRNA Array y                     13 pairs              *P*\<0.01 FC\>2     27                    23
  Ramon' LA (13)             2011   Spain       TaqMan assay                                58 pairs+38 N         *P*\<0.05           3                     3
  Hawkins SM (14)            2011   USA         TaqMan assay                                9 N and 10 E          *P*\<0.01 FC\>1.5   10                    12
  Petracco R (15)            2011   USA         qRT-PCR                                     50 N+32 E             *P*\<0.05           2                     0
  Dai L (16)                 2012   China       qRT-PCR                                     12 pairs+12 N         *P*\<0.01           1                     0
  Liu S (17)                 2012   China       TaqMan MicroRNA Array                       31 pairs+27 N         *P*\<0.05           0                     1
  Lin SC (18)                2012   China       qRT-PCR                                     10 pairs+37 N+17 E    *P*\<0.05           1                     0
  Shen L (19)                2013   China       qRT-PCR                                     23 pairs+15 N         *P*\<0.05           0                     2
  Laudanski P (20)           2013   Poland      TaqMan MicroRNA Array                       21E+25N               *P*\<0.05 FC\>2     2                     13

E= endomeriosis, N=control, pairs= paired eutopic and ectopic endometrial tissues

Determination of the consistently reported miRNAs {#sec2-5}
-------------------------------------------------

A total of 134 differentially expressed miRNAs were obtained in the 12 miRNAs expression profiling studies that compared endometriosis tissues with normal tissues, with 28 miRNAs reported in at least two studies, including 4 consistently reported up-regulated miRNAs(mir-202, mir-365, mir-1 and mir-150), 9 consistently reported down-regulated miRNAs (mir-23b, mir-200a, mir-200b, mir-200c,mir- 15b, mir-106b, mir-196b, mir-141, mir-375) ([Table 2](#T2){ref-type="table"}). And 15 inconsistently reported direction miRNA ([Table 3](#T3){ref-type="table"}).

###### 

Consistently reported miRNAs (n = 13) in profiling studies (endometriosis tissues versus eutopic tissues or normal tissues)

  Direction of expression   miRNA name   Number of studies with same direction   Total number of tissue samples   *P-*value
  ------------------------- ------------ --------------------------------------- -------------------------------- -----------
  ↑                         mir-202      2                                       32                               \<0.001
  ↑                         mir-365      2                                       20                               \<0.05
  ↑                         mir-1        2                                       20                               \<0.05
  ↑                         mir-150      2                                       20                               \<0.001
  ↓                         mir-23b      3                                       40                               \<0.001
  ↓                         mir-200b     3                                       39                               \<0.05
  ↓                         mir-200a     3                                       39                               \<0.05
  ↓                         mir-200c     2                                       32                               \<0.05
  ↓                         mir-141      2                                       26                               \<0.05
  ↓                         mir-375      2                                       32                               ≤0.01
  ↓                         mir-106b     2                                       34                               \<0.05
  ↓                         mir-196b     2                                       20                               ≤0.05
  ↓                         mir-15b      2                                       64                               \<0.05

###### 

Inconsistently reported miRNAs (n=15) in profiling studies (endometriosis tissues versus normal tissues)

  Direction of expression   miRNA name   Number of studies with same direction   Total number of tissue samples   *P*-value
  ------------------------- ------------ --------------------------------------- -------------------------------- -----------
  ↑                         mir-100      3                                       39                               ≤0.01
  ↓                         mir-100      1                                       8                                \<0.05
  ↑                         mir-17-5p    1                                       9                                \<0.05
  ↓                         mir-17-5p    3                                       79                               \<0.05
  ↑                         mir-29c      3                                       39                               \<0.01
  ↓                         mir-29c      1                                       8                                \<0.05
  ↑                         mir-20a      1                                       49                               \<0.05
  ↓                         mir-20a      3                                       78                               ≤0.05
  ↑                         mir-126      2                                       20                               \<0.05
  ↓                         mir-126      2                                       39                               \<0.001
  ↑                         mir-145      2                                       20                               \<0.05
  ↓                         mir-145      2                                       29                               \<0.05
  ↑                         mir-125a     2                                       65                               \<0.001
  ↓                         mir-125a     1                                       8                                \<0.05
  ↑                         mir-99a      2                                       20                               \<0.001
  ↓                         mir-99a      1                                       8                                \<0.05
  ↑                         mir-143      2                                       20                               \<0.001
  ↓                         mir-143      1                                       8                                \<0.05
  ↑                         mir-23a      1                                       9                                0.006
  ↓                         mir-23a      2                                       31                               0.006
  ↑                         mir-222      1                                       41                               \<0.001
  ↓                         mir-222      2                                       29                               \<0.05
  ↑                         mir-199a     1                                       13                               ≤0.01
  ↓                         mir-199a     2                                       20                               \<0.05
  ↑                         mir-125b     1                                       31                               \<0.05
  ↓                         mir-125b     1                                       8                                \<0.05
  ↑                         mir-21       1                                       58                               \<0.01
  ↓                         mir-21       1                                       8                                \<0.01
  ↑                         mir-221      1                                       13                               ≤0.01
  ↓                         mir-221      1                                       8                                \<0.05

Pathway analysis of miRNA targets {#sec2-6}
---------------------------------

By using four target prediction tools (TargetScan, PicTar, miRanda, and miRDB), 9882 candidate genes were predicted for 13 inconsistently reported miRNAs. And all the predicted candidate genes were analyzed by pathways enriched analysis. KEGG and Panther pathways enrichment analysis showed that 9882 endometriosis-related miRNA targets were mainly cancer-related pathways, endocytosis, Wnt signalling pathway, and angiogenesis ([Table 4](#T4){ref-type="table"}).

###### 

Top ten of the significant GO processes, KEGG pathways and Panther pathways enriched with miRNA targets involved in endometriosis

  GO processes   Process                                                                FDR             Target number
  -------------- ---------------------------------------------------------------------- --------------- ---------------
  GO:0006355     Regulation of transcription, DNA-dependent                             5.55032e-182    963
  GO:0007165     signal transduction                                                    2.72922e-125    694
  GO:0007275     Multicellular organismal development                                   7.66 e -100     557
  GO:0045944     Positive regulation transcription of from RNA polymerase II promoter   4.43532e-86     378
  GO:0007399     Nervous system development                                             3.20348e-70     280
  GO:0007155     Cell adhesion                                                          8\. 37777e-68   342
  GO:0045893     Positive regulation of transcription, DNA dependent                    3.78756e -66    301
  GO:0007268     Transmission synaptic                                                  6.22556e-57     250
  GO:0055085     Transmembrane transport                                                9\. 4472e-56    353
  GO:0000122     Negative regulation transcription of from RNA polymerase II promoter   1\. 0109e-55    263

  KEGG pathways   Pathway                            FDR            Target number
  --------------- ---------------------------------- -------------- ---------------
  KEGG:5200       Pathways in cancer                 3.54381e-53    218
  KEGG:4144       Endocytosis                        5.04266e-44    144
  KEGG:4360       Axon guidance                      5.91358e-35    101
  KEGG:4810       Regulation of actin cytoskeleton   2.65172e-34    140
  KEGG:4010       MAPK signaling pathway             4.03001e-33    162
  KEGG:4080       Neuroactive ligand receptor        5.56784e-29    158
  KEGG:4310       Wnt signaling pathway              5.87106e-29    105
  KEGG:4510       Focal adhesion                     8.49293e-29    127
  KEGG:4060       Cytokine signaling pathway         4.84554 e-27   151
  KEGG:4062       Chemokine signaling pathway        1.23502e-26    119

  Panther pathways   Pathway                                                                                      FDR             Target number
  ------------------ -------------------------------------------------------------------------------------------- --------------- ---------------
  P00057             Wnt signalling pathway                                                                       3.24683e-35     173
  P00005             Angiogenesis                                                                                 3.83276e-34     113
  P00034             Integrin signalling pathway                                                                  4.17619e-29     109
  P00047             PDGF signalling pathway                                                                      6.46839e-25     90
  P00031             Inflammation mediated by chemokine cytokine signaling pathway                                3.43609e-23     119
  P00026             Heterotrimeric G-protein signaling pathway\-\--Gi alpha and Gs, and alpha mediated pathway   3.32868e-23     98
  P00012             Cadherin signalling pathway                                                                  2\. 44252e-19   88
  P00018             EGF receptor signaling pathway                                                               2.29847e-18     75
  P00021             FGF signaling Pathway                                                                        7.78382e-18     72
  P00004             Alzheimer disease \--presenilin pathway                                                      4.27409e-17     75

Discussion {#sec1-4}
==========

In this paper, we adopt a meta-analysis to screen endometriosis-related miRNAs from miRNA expression profile data of independent profiling studies, and to obtain conservative target predictions for all miRNAs lists of interest using four up-to-date prediction algorithms (TargetScan, PicTar, PicTar, miRanda and miRDB). And pathway enrichment analysis using different target prediction algorithms were concordant for all of the consistently expressed miRNAs. We found out a meta-signature of four up-regulated and nine down-regulated miRNAs. Although the selected method for miRNA expression meta-analysis relates to analysis of the primary expression parameters, such method was often not possible due to the unavailability of the primary data. A great number of miRNAs known in the present and different technical platforms adopted in certain study make the appropriate synthesis of primary data very complex. Moreover, the relatively small sample sizes of microarray data may have resulted in inconformity of biological consequences. A meta-analysis method could eliminate these disadvantages and directly compare original data extracted from different technical platforms ([@ref21]).

All the data from the 12 published studies consisted of more than 317 endometriosis and eutopic or normal tissue samples were analyzed directly, and a series of early researches ([@ref2], [@ref11], [@ref12], [@ref14]) were analyzed with less than ten specimens, which may have unreliable results. Ohlsson Teague *et al* ([@ref22]) assessed miRNA expression by microarray analysis in seven paired ectopic and eutopic endometrial tissues and identified 14 up-regulated and eight down-regulated miRNAs in endometriosis tissues. Pan *et al* ([@ref2]) identified 48 differently expressed miRNAs in a microarray analysis of endometrium of women with and without endometriosis, and mir-23b down-regulation. Compared with nonendometriosis control endometrium, mir-200b expression level decreased obviously in endometriosis ([@ref14]).

Angiogenesis is the basis of the occurrence and development in endometriosis. Just as tumor, implantation metastasis of endometriosis is based on new neurovascular formation and proliferation, invasion of extracellular matrix, and lesion formation. Recent studies revealed that miRNA may involve in regulation of angiogenesis, and some miRNAs have the distinction of anti-vasoformation, such as mir-15b, mir-16, mir-221, and mir-222. Interestingly, the results suggest that mir-200 family members (mir-200a, mir-200b, mir-200c, mir-141, which were known to be cancer-related miRNAs down-regulated, while expression of some others (mir-21 ([@ref2], [@ref13]), mir-199a ([@ref2], [@ref13], [@ref16])) were inconsistently reported in the selected studies. Some miRNAs which have been specifically investigated in several studies (such as miR-17-5p, mir-23a,mir-23b ([@ref19], [@ref23]); mir-20a([@ref18]); mir-126([@ref17]); mir-135a, mir-135b ([@ref15])) were found among both up-regulated and down-regulated. All mirRNA-200 family members (miR-200a, miR-200b, miR-200c, miR-141, miR-429) were found down-regulated, and reached the statistical significance in our analysis, of course, mir-429 was only reported in just one study. Currently, our analysis is limited to comparison of endometriosis and eutopic or normal control tissue. The miR-200 family has been reported to be a fundamental regulator of epithelial-mesenchymal transition, thus enhancing their roles in cancer progression. As a founding member in miR-200 family, miR-200b attracts much focus in carcinogenesis in recent years. Down-regulation of miR-200b has been detected in several malignancies ([@ref24]-[@ref26]) and in endometriosis ([@ref27]). The set of miRNAs with significantly decreased expression levels include all members of the miR-200 family known to be involved in the epithelial to mesenchymal transition process ([@ref28]).

From the clinical viewpoint, it would be meaningful if the discovery of targets correlated with patient diagnosis, therapy and prognosis. These meta-signature miRNAs and gene-to-behavior pathway affected by them are potential candidates as diagnostic and therapeutic agents in endometriosis. Our analysis also concentrated on the challenges connected with the development of miRNA-based tests and emphasizes to the importance of strict inspection of the results before conducting clinical trials. Perez-Iratxeta *et al* ([@ref29]) applied a combination of data mining and gene ontology to develop a scoring system for discovering disease-associated genes based on text descriptions of genetically inherited diseases and functional annotations of genes. The scoring showed that the chance of validating potential gene is high for some diseases. Mohammadi *et al* ([@ref30]) used microarray data mining and gene ontology to identify disease-causing genes, and predicted marker genes with high accuracy. It indicates that the above method of comparing data is derived from different organisms in studies of disease and human health. Here we showed some familiar and novel pathways for endometriosis, including the pathways in cancer, endocytosis and axon guidance. New visions were also provided into Wnt signaling, angiogenesis, and integrin signaling pathway. These pathways that regulate stem cell transformation indicate the role of miRNAs in endometriosis cell deregulation and development. Therefore, some of these miRNAs may be selected as diagnostic index or acted as therapeutic agent for endometriosis. MiRNAs appear to be potent regulators of gene expression in endometriosis and its associated reproductive disorders, raising the prospect of using miRNAs as biomarkers and therapeutic agent in endometriosis.

It should be emphasized that there were some limitations in our analysis. In this study, the inclusion of researches was based on different assay types. The total number of tissues from available data was relatively small, and tissues included endometriosis tissue, eutopic endometrium, and normal tissue. We extracted data retrieved from different studies, and. published large prospective researches were unattainable for endometriosis. In addition, there were only 12 eligible studies in our meta-analysis, which may also lead to a bias in the results.

Conclusion {#sec1-5}
==========

By systematic enrichment analysis, we found that these differently expressed miRNAs and gene are potential biomarkers of endometriosis. Our analysis also highlights the challenges connected with the development of miRNA-based tests and emphasizes the need for rigorous evaluation of the results before proceeding to clinical trials.
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